Abstract 2089P
Background
Febrile neutropenia (FN) resulting from myelosuppressive chemotherapy drugs, have the potential to necessitate dose reduction or treatment delays, thus compromising the overall efficacy of treatment. This study aims to analyze the incidence of FN and related adverse drug reactions in cancer patients who receive prophylaxis with PEG-rhG-CSF (a long-acting granulocyte colony-stimulating factor).
Methods
This real-world study was conducted as a multicenter, retrospective, observational research involving adult cancer patients who received chemotherapy with PEG-rhG-CSF prophylactic. The study focused on several variables, including baseline characteristics and incidence of FN. Descriptive analysis was performed by using IBM SPSS Statistics 27.
Results
24,199 patients were enrolled from 575 hospitals across China between June 2022 and January 2023. The chemotherapy cycle records encompassed 1to 20 cycle. Among the enrolled patients, breast cancer was the most prevalent tumor type, accounting for 33.6% (N=8,131) of the cases. FN incidence across all cycles was 0.054% and it was 0.055% and 0.053% among patients receiving PEG-rhG-CSF as primary and secondary prophylaxis. These rates were significantly lower than the previously reported data of 13% to 21% from a retrospective cohort study involving patients with or without prophylaxis. Overall, FN occurred across the first to eighth cycles with the highest incidence observed in cycle 1 (52.50%). 1,659 records (2.25%) reported adverse events related to PEG-rhG-CSF. The most commonly observed adverse effect was musculoskeletal pain, accounting for 1.53% of the cases, followed by fatigue(0.60%) and allergic reactions(0.07%). Furthermore, 90.78% of adverse reactions were categorized as primary or secondary adverse reactions.
Conclusions
Under PEG-rhG-CSF prophylaxis, cancer patients exhibited a low incidence of FN which primarily occurred in the initial cycle of chemotherapy. Importantly, the administration of PEG-rhG-CSF was well tolerated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06